Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off ...